Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...
Investor's Business Daily on MSN
Wave Life Sciences just targeted fat loss, specifically. Shares skyrocketed 80%.
Wave Life Sciences stock shot a year-high Monday on promising results for an entirely new mechanism that could target fat ...
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback